GoodRx Holdings, Inc.

Listed Company

GDRXCIK 0001809519NasdaqAcceleratedServices-Computer Processing & Data PreparationDelawareFY ends Dec 31

Period

FY 2025

Revenue

$796.85M

Net Income

$30.44M

Total Assets

$1.40B

Equity

$616.26M

Shares Out

—

Op. Cash Flow

$167.90M

GDRX$3.13−33.83% · past yearDBEQ Basic

Daily closing prices

Business

GoodRx Holdings, Inc. is a consumer-focused digital healthcare platform that helps Americans save money and time when filling medications. The company operates a prescription price-comparison marketplace that aggregates and normalizes pricing data from PBMs, pharmacies, and other healthcare sources, enabling consumers to access discounted prescription prices through GoodRx codes. GoodRx also offers subscription services (Gold, RxSmartSaver+, condition-specific programs), telehealth services via GoodRx Care, and a pharma direct offering that integrates manufacturer affordability solutions (copay cards, patient assistance programs, direct pricing) into its platform. The company serves consumers, healthcare providers, pharmacies, PBMs, and pharmaceutical manufacturers across the United States.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	797	792	750	767	745
Cost of revenue, exclusive of depreciation and amortization presented separately below	58	48	67	65	47
Product development and technology	121	124	136	143	126
Sales and marketing	332	367	341	358	370
General and administrative	114	118	126	145	155
Depreciation and amortization	85	70	108	54	35
Total costs and operating expenses	709	726	777	765	732
Operating income (loss)	87	66	−27	2	13
Other income (expense)	718,000	−3	−4	0	0
Loss on extinguishment of debt	0	−2	0	0	0
Interest income	11	23	32	9	59,000
Interest expense	−43	−53	−57	−34	—
Total other expense, net	−31	−34	−29	−25	−24
Income (loss) before income taxes	57	31	−56	−23	−10
Income tax (expense) benefit	−26	−15	47	−10	−15
Net income (loss)	30	16	−9	−33	−25
Basic (in usd per share)	0.09	0.04	−0.02	−0.08	−0.06
Diluted (in usd per share)	0.09	0.04	−0.02	−0.08	−0.06
Basic (in shares)	356	386	410	413	410
Diluted (in shares)	357	392	410	413	410

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-09-30
Cash and cash equivalents	262	448	672	757	—
Accounts receivable, net	236	146	144	117	—
Prescription reimbursement assets	98	23	—	—	—
Prepaid expenses and other current assets	47	42	57	45	—
Total current assets	643	659	873	920	—
Property and equipment, net	12	13	16	20	—
Goodwill	430	411	411	412	—
Intangible assets, net	64	52	61	120	—
Capitalized software, net	139	125	95	70	—
Operating lease right-of-use assets, net	29	28	30	9	20
Deferred tax assets, net	57	77	65	0	—
Other assets	29	24	38	27	—
Total assets	1,404	1,388	1,589	1,605	—
Accounts payable	19	14	36	18	—
Prescription reimbursement liabilities	130	16	—	—	—
Accrued expenses and other current liabilities	87	83	71	48	—
Current portion of debt	5	5	9	7	—
Operating lease liabilities, current	5	6	6	4	—
Total current liabilities	246	124	123	76	—
Debt, net	483	487	648	652	—
Operating lease liabilities, net of current portion	50	46	48	54	20
Other liabilities	9	7	8	8	—
Total liabilities	788	663	827	790	—
Commitments and contingencies	—	—	—	—	—
Preferred stock, $0.0001 par value; 50,000 shares authorized and nil shares issued and outstanding at December 31, 2025 and December 31, 2024	0	0	0	0	—
Common stock, $0.0001 par value; Class A: 2,000,000 shares authorized, 107,088 and 105,946 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively; and Class B: 1,000,000 shares authorized, 233,964 and 276,869 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	34,000	38,000	40,000	40,000	—
Additional paid-in capital	2,027	2,166	2,219	2,263	—
Accumulated deficit	−1,411	−1,441	−1,457	−1,449	—
Total stockholders' equity	616	725	762	815	—
Total liabilities and stockholders' equity	1,404	1,388	1,589	1,605	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Amortization of debt issuance costs and discounts	2	2	3	3	3
Non-cash operating lease expense	4	4	4	—	—
Stock-based compensation expense	77	99	105	120	160
Deferred income taxes	20	−12	−66	−497,000	13
Loss on operating lease assets	4	0	1	13	1
Loss on disposal of capitalized software	0	0	8	0	0
Loss on minority equity interest investment	0	0	4	0	0
Other	2	0	1	—	—
Accounts receivable	−88	−2	−26	1	−44
Prescription reimbursement assets	−75	−7	−15	—	—
Prepaid expenses and other assets	−8	14	−17	−14	17
Accounts payable	4	−16	12	−874,000	4
Prescription reimbursement liabilities	114	10	5	—	—
Accrued expenses and other current liabilities	1	10	21	−5	14
Operating lease liabilities	−6	−5	−3	−4	−2
Other liabilities	2	−1	914,000	2	−711,000
Net cash provided by operating activities	168	184	138	147	179
Purchase of property and equipment	−4	−1	−1	−4	−5
Acquisitions	−43	0	0	−157	−140
Capitalized software	−70	−69	−55	−51	−30
Other	−3	0	0	—	—
Net cash used in investing activities	−120	−70	−56	−210	−179
Proceeds from long-term debt	0	472	0	0	0
Payments on long-term debt	−5	−639	−5	−7	−7
Payments of debt issuance costs	0	−3	0	0	0
Repurchases of Class A common stock	−216	−159	−104	−102	0
Proceeds from exercise of stock options	61,000	19	6	9	35
Employee taxes paid related to net share settlement of equity awards	−14	−30	−65	−21	−58
Proceeds from employee stock purchase plan	1	2	1	0	0
Net cash used in financing activities	−234	−337	−167	−120	−31
Net change in cash and cash equivalents	−187	−224	−85	−184	−30
Income taxes paid, net of refunds received	13	24	17	4	−18
Interest paid	41	55	49	31	20
Right-of-use assets obtained in exchange for operating lease liabilities	9	2	52,000	22	3
Stock-based compensation included in capitalized software	15	16	13	9	8
Capitalized software included in accounts payable and accrued expenses and other current liabilities	8	8	8	4	1
Capitalized software transferred from prepaid assets	0	0	6	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is GoodRx Holdings, Inc.'s CIK number?

GoodRx Holdings, Inc.'s SEC CIK number is 0001809519 (1809519). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find GoodRx Holdings, Inc.'s SEC filings?

All of GoodRx Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did GoodRx Holdings, Inc. last report earnings?

GoodRx Holdings, Inc. (GDRX) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001809519-26-000110). This is GoodRx Holdings, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is GoodRx Holdings, Inc.'s most recent earnings 8-K?

GoodRx Holdings, Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001809519-26-000110. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View GoodRx Holdings, Inc.'s latest earnings 8-K →
Look up any company's CIK number →